
Ulcerative colitis red flags as TOWIE star shares health battle
Chloe Meadows openly discussed her struggle with ulcerative colitis on Dr. Oscar Duke's Bedside Manners podcast, revealing that she ignored warning signs for almost ten years. The 33-year-old reality star recalled noticing blood in her stool at the age of 16 while attending boarding school.
"I remember I told my mum and was like there is quite a lot of blood down the toilet," Chloe, who once starred in The Only Way Is Essex, said. "I'm not really sure what is going on and she, of course, said go to the doctors. I went to the doctors and they said that I would have to have a colonoscopy.
"The doctor referred me and I got this letter, and this is awful, but I got this letter and I just never went to the appointment because I was terrified. It would stop for periods of time so that the blood would go away.
"I'd be like, 'Oh, cool, it's gone away, I'm better. There's nothing wrong with me'. I'd go through years where it wouldn't happen and then it would happen again, and then it would stop again.
"I just got on with it and ignored it. I think I was scared of having any procedure done." The podcast episode underscored the importance of recognising this condition, pointing out how frequently people dismiss or overlook symptoms when they occur.
To gain further insights into ulcerative colitis, we interviewed Pearl Avery, the IBD (inflammatory bowel disease) nursing lead at Crohn's & Colitis UK, who discussed several typical red flags to be aware of.
Ulcerative colitis explained
"Ulcerative colitis is a type of IBD where parts of the large bowel – the colon and rectum – become inflamed and ulcerated," Avery said. "This can cause worrying symptoms like blood in your poo and frequent, urgent diarrhoea as well as weight loss (because you're struggling to absorb nutrients) and fatigue.
"Usually, the immune system protects the body, but it's thought that in colitis it goes wrong and starts attacking the bowel." Despite this, Avery emphasised that its exact cause remains largely unknown.
She went on: "We don't know for sure what causes colitis or Crohn's, but researchers believe it's a mix of genes, bacteria in the gut and something in the environment that triggers it. There are all sorts of exciting studies happening now to unlock the mystery of what causes IBD and hopefully one day find a cure."
Typical red flags to look out for
While each person experiences colitis in their own way, certain warning signs should not be ignored. "Some symptoms to look out for include blood in your poo (more than once), urgent and frequent diarrhoea, unexplained weight loss, joint pain and fatigue," Avery said.
"Constipation can also be a symptom of colitis, as can stomach pain. There is a really handy symptom checker on the Crohn's & Colitis UK website which takes just 30 seconds to complete and provides support and guidance on when to see a doctor and what to say when you get there."
When you should seek medical advice
Although symptoms can be easily brushed off as a 'dodgy tummy' or something consumed, Avery advised consulting an expert promptly. "If you are seeing blood in the toilet when you poo, having frequent diarrhoea, or even waking up in the night to rush to the loo, then it's time to speak to someone about it," she said.
"We know that it's taking too long for people with Crohn's and colitis to be diagnosed, but the sooner you start that process and ask for help, the better."
Diagnosing ulcerative colitis
If colitis is suspected, various tests might be suggested. Avery explained: "One is a straightforward faecal calprotectin test, which analyses a sample of your poo to work out how much inflammation you've got going on in your bowel.
"Then you might be referred for a colonoscopy, which is done in the hospital and involves having a scope, or tiny camera, put into your bottom to look around the colon and rectum."
Treatment options
Currently, a cure for colitis is not available; however, several treatments exist to alleviate its symptoms. These treatments include immunosuppressants and steroids.
Avery continued: "There are new drugs being developed all the time, which is really encouraging. Some people with colitis end up having surgery to have part of their bowel removed and a stoma fitted.
"Those operations are life-changing, but that's not a bad thing, because for many patients the change is very positive, and they tell us they wish they had had the surgery sooner and it has given them a new lease of life."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Glasgow Times
4 hours ago
- Glasgow Times
Three new cancer drugs approved for use for NHS Scotland
The Scottish Medicines Consortium (SMC) approved the drug brentuximab vedotin, also known as Adcetris, which can be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. (Image: Image from PA) SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. READ NEXT: Rock band to play huge headline show in Glasgow Graeme Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' READ NEXT: Two teens nicked after 'DPD van chased' through streets by cops However, the Scottish Medicines Consortium (SMC) said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. It also rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Bryson said: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Joseph Carter, head of the charity Asthma + Lung UK Scotland, added: 'If the cost effectiveness of dupilumab for use by NHS Scotland can be improved, we are hopeful that the Scottish Medicines Consortium will revisit its decision. 'With an estimated 241,000 people living with COPD in Scotland, there is hope that this drug could help guide research for other targeted therapies. 'More lung research is desperately needed to enable a breakthrough to help better control or even cure COPD.'

The National
8 hours ago
- The National
Three new cancer drugs approved for use by NHS Scotland
The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. READ MORE: Jewish staff at Scottish universities call for full divestment from Israel Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Joseph Carter, head of the charity Asthma + Lung UK Scotland, said: 'If the cost effectiveness of dupilumab for use by NHS Scotland can be improved, we are hopeful that the Scottish Medicines Consortium will revisit its decision. 'With an estimated 241,000 people living with COPD in Scotland, there is hope that this drug could help guide research for other targeted therapies. 'More lung research is desperately needed to enable a breakthrough to help better control or even cure COPD.'


STV News
9 hours ago
- STV News
Three new cancer drugs approved for use for NHS Scotland
Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country